What Are Investigators Responsible for When Reviewing the IB?

Clinical investigators play a critical role in ensuring the ethical and scientific integrity of clinical trials. A central aspect of their responsibility includes the thorough review of the Investigator’s Brochure (IB), which provides comprehensive details on the investigational product. Reviewing and understanding the IB is not merely a procedural formality—it is a regulatory expectation, a Good Clinical Practice (GCP) requirement, and a cornerstone of subject safety and informed consent.

This tutorial provides step-by-step guidance on what investigators must do during IB review, how sponsors and monitors should support this process, and how trial sites can remain compliant during audits and inspections.

Why IB Review Matters for Investigators:

The IB is a living document that summarizes nonclinical and clinical data, including safety, pharmacology, dosing, and known risks. Review of this document ensures investigators can:

• Understand the investigational product’s risk profile
• Communicate effectively with participants during informed consent
• Recognize adverse events and safety signals during the trial
• Follow protocol-specific guidance grounded in product understanding

As per USFDA and ICH E6(R2) guidelines, investigators are accountable for ensuring their familiarity with the IB content and applying that knowledge in patient care decisions during trials.

GCP Requirements for IB Review:

According to ICH GCP (Section 4), the principal investigator must:

• Be thoroughly familiar with the investigational product(s) as described in the IB
• Review any updated versions of the IB as they become available
• Ensure all delegated personnel are also trained on and familiar with the IB

This requirement supports investigator diligence in protecting trial participants and conducting the study with scientific validity and regulatory alignment.

How to Review the IB Effectively:

Investigators should not just sign a receipt of the IB—they must actively engage with its contents. Recommended review practices include:

1. Schedule a dedicated IB review session: Block time for reading and understanding all key sections of the IB.
2. Highlight relevant product risks and interactions: Pay attention to safety signals, black-box warnings, and contraindications.
3. Compare with the current protocol: Ensure consistency between protocol and IB (e.g., dosing, route of administration).
4. Discuss with study staff: Hold team briefings to ensure understanding across sub-investigators and site staff.
5. Document the review: Sign and date the IB log and note key observations in the site file.

Make use of IB review checklists from your SOPs and ensure your process aligns with expectations laid out in pharma SOP templates.

Responsibility for Acknowledgment and Version Control:

When a new version of the IB is released (often due to updated safety data or study amendments), investigators must:

• Receive the updated version via the sponsor or CRO
• Document receipt in an IB acknowledgment form
• Retain both the previous and current versions in the Investigator Site File (ISF)
• Ensure all applicable team members are notified and trained

The acknowledgment must include version number, date received, and investigator signature. Sponsors often track these via Clinical Trial Management Systems (CTMS) or secure portals for GMP documentation purposes.

What Investigators Must Pay Attention To in the IB:

While reviewing, key areas of focus should include:

• Indications and Pharmacodynamics: Ensure clarity on the drug’s intended use and mechanism of action
• Nonclinical Data: Summarize any animal study findings relevant to humans
• Human Clinical Data: Look for previous trial outcomes, including any adverse events
• Known Risks: Document all side effects and risk mitigation strategies
• Dose Justification: Review rationales for starting and maximum dose levels

This step ensures that all trial stakeholders are aligned and any discrepancies with protocol or informed consent forms can be flagged proactively.

Training Site Staff on IB Content:

It is not sufficient for only the principal investigator to review the IB. Delegated staff involved in drug administration, safety reporting, or patient interaction should be trained on its key contents.

Recommended practices:

• Include IB review in Site Initiation Visit (SIV) training
• Use visual summaries or slide decks for site staff
• Maintain signed training logs for each IB version distributed
• Link IB updates with study stability documentation to ensure integrated compliance

Audit Expectations for IB Review:

Regulatory inspectors, including those from EMA and Health Canada, will evaluate how well IB review responsibilities are documented at site level.

Common audit questions include:

• When did the site receive the current IB version?
• Was the review documented in the acknowledgment form?
• Were all relevant staff trained on IB contents?
• How are older versions archived?
• Is there an SOP guiding IB handling and updates?

Failing to answer these can result in audit observations or non-compliance citations.

Integration with SOPs and Document Control Systems:

Clinical sites should have a well-defined SOP that outlines:

• Process for receiving and acknowledging IBs
• IB review responsibilities across team roles
• Timelines for documentation and training after an update
• Storage and archival procedures for previous versions
• Interface with electronic document control systems

This aligns with best practices found on validation and SOP systems for trial compliance.

Conclusion:

Reviewing the IB is not just a checkbox item—it’s an ethical and regulatory responsibility for investigators. Being fully familiar with the IB ensures better protocol adherence, accurate informed consent processes, and ultimately, enhanced patient safety. Sponsors must support this process with timely distribution, training materials, and compliant tracking mechanisms.

For clinical investigators and study staff, developing the habit of critical review and proper documentation of IB engagement can significantly elevate the quality and compliance of clinical trial operations.